By Daniel Joseph Price and Gudrun Birk
With a mean particle size of 80 μm, Parteck SRP 80 excipient is a PVA optimized for drug dissolution, easy handling, good flowability and good reproducibility with respect to both sustained API release and direct compression (DC) manufacturability. Batch-to-batch consistency ensures consistent quality and enables use of QbD to further minimize risks in development and manufacture. Parteck SRP 80 excipient is also compliant with Ph. Eur., USP, ChP and JPE monographs. This white paper describes the use of PVA-based Parteck SRP 80, a functional excipient specifically developed for matrix-based sustained release oral solid dose formulations.